This descriptive study used a Japanese claims database covering April 2014 to March 2024. It included 37,526 adults aged 40 or over who started denosumab and stopped after at least two doses. Stopping meant a gap of more than 240 days after the last dose. Within a year, 29.6% resumed denosumab after that gap, 50.9% had no further treatment and 16.3% began sequential therapy. Oral bisphosphonates (26.7%) and romosozumab (22.2%) were the commonest sequential therapies. The study did not compare fracture risk between treatment patterns, though 5.4% had a fragility fracture within a year.
Why it is interesting: Half of patients who stopped denosumab had no further osteoporosis treatment within a year. Timing differed by drug, with romosozumab most often started 180-209 days after stopping.
Cite this item
BibTeX
Free sign-up. A digest of the new papers twice a week, grouped by domain.